Yu Guang Tan

[Yu Guang Tan @YuGuangTan1]

A rewarding weekend spent immersing in surgical innovation with robotic SP pioneers. SP is not about SINGLE incision, it’s the endless potential that we can bring to patients who would have been previously written off.Only the beginning @HUMCUrology @mdstifelman @RoboticsUrology

[Jame Abraham, MD, FACP @jamecancerdoc]

Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries - Sung - 2026 - CA: A Cancer Journal for Clinicians - Wiley Online Library https://t.co/qWLgQyaBWN @JournalCancer @OncoAlert

[Mutahar Ahmed @RoboticsUrology]

Amazing! 3 outstanding live cases:PNx,RALP &TV RASP moderated by an outstanding faculty. Great discussions with bright young minds,covering SP pearls across multiple procedures, including LAA SP RPLND.Fantastic education, collaboration..SP is present and future! @HUMCUrology

[Alireza Ghoreifi, MD @alirezaghoreifi]

Tonight, we celebrated Dr. Cary Robertson’s retirement. Over 30 years at Duke Urology @DukeGUCancer and a remarkable legacy in urologic oncology!
@JuddMoul @michaelabern @mbrothberg @YuGuangTan1

[IBCG @IBCG_BladderCA]

Congratulations Dr Tan. We look forward to welcoming you to the IBCG retreat this summer.

@UroDocAsh @UrogerliMD @shilpaonc @pjhensley11 @spsutkaMD @mouwlab @AndreaNecchi @AmirHorowitz @LAUrology_NL

[Yu Guang Tan @YuGuangTan1]

Humbled to receive the travel award to join the @IBCG_BladderCA retreat this summer! Eager to learn and actively contribute to the community.

[Urologic Oncology @UrolOncol]

🔥@UrolOncol June issue!

Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis by @YuGuangTan1 and @UroDocAsh et al

🔗https://t.co/nAXeHcpdm6

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Fabulous presentations by the panel. Well done!

Informal #AUA26 audience vote: 95+% would not avoid RC at this time.

Studies ongoing, need more data
My conclusion: 👇

[Yu Guang Tan @YuGuangTan1]

@UroDocAsh @yeowyy @TheLancet True academic rigour should be in the spirit of improving clinical outcomes, reflect real world practice and advance science, not in the act of building one’s CV by deceiving the community. What a pity!

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

“A 2025 paper on ureteroileal anastomotic techniques … contained 60% fabricated references …”

Fabricated citations: an audit across 2·5 million biomedical papers - @TheLancet
https://t.co/JUN1edZm7k #AUA26

[Yu Guang Tan @YuGuangTan1]

https://t.co/nL7EF4Rge9
What started as clinical observation:m-NMIBC after previous utuc responds poorer to BCG since starting the BCa service @SingHealthSG has matured into two publications: a cohort study and a SRMA. Important for trial considerations @UroDocAsh @DrChenKenneth

[Yu Guang Tan @YuGuangTan1]

@alirezaghoreifi @SES_AUA @michaelabern @DukeUrology Congrats!!

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

@tompowles1 @weoncologists @Uromigos @kalasri3 Thanks for the shoutout Tom.
We need to help our patients and deliver a unified message:
The OS advantage seen with EV+P
relies on consolidation with Radical
Cystectomy + PLND
(not observation, not TMT)
#EAU26

[Yu Guang Tan @YuGuangTan1]

@UroDocAsh @ParamMariappan @niyatilobo @chats69 Fully agree! We are incorporating routine QOL assessment (eortc and nmibc) for patients at the start/end induction and at every maintenance. About 50 patients as we speak. And correlating with their AE, adherence and overall efficacy. Will share with you when data is ready!

[Sabine D. Brookman-May @brookmans76]

🚨 Final THOR-2 results out in @EUplatinum - #Erdafitinib in FGFR-altered #NMIBC
✅ HR papillary NMIBC:
• Median RFS not reached vs 11.6 mo with intravesical chemo
• HR 0.25 (75% recurrence risk reduction)
✅ HR CIS ± papillary:
• CR 94% at 8 wks | 81% at 32 wks
• Median DoR 23.3 months
✅ Intermediate-risk NMIBC:
• CR ~89%
• Durable responses - median DoR not reached
👉Targeted systemic therapy showing real durability in IR and HR FGFR+ NMIBC
#BladderCancer #TargetedTherapy @EUplatinum @oncodaily @urotoday @siadaneshmand @PignotG @nikhilvasdevuro @JimCatto @JNJInnovation

[USC Urology @USC_Urology]

Dr. Sia Daneshmand discusses management of high risk non-muscle-invasive bladder cancer. @siadaneshmand #practicalurology26

[Max Diehn, MD/PhD @max_diehn]

We’re excited to share our latest study describing a new urine tumor DNA (utDNA) liquid biopsy method for #BladderCancer that accounts for the field effect, a key challenge for urine MRD detection. Out today in @Cell: https://t.co/o7CKlnd4Rn 🧵 (1/14) #LiquidBiopsy

[Yu Guang Tan @YuGuangTan1]

Sharing a recent interview by GU Oncology at SUO meeting.
MIS-ILND showed similar nodal yield, +LN count, RFS and demonstrated
- much lower Cx rate (esp major Cx) and avg 4 days shorter LOS
https://t.co/kr2PqYFPin

[Karine Tawagi MD @DrKarineTawagi]

Very exciting news for patients with cisplatin-ineligible MIBC!! EV/P approved today!

#EV303
80% T3-T4a
12% ECOG 2
EFS 0.40
OS 0.50
pCR 57% vs 8.6%

❓could we preserve some of these bladders
❓extrapolate #Imvigor011 using ctDNA to guide adjuvant tx? #MODERN will help

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality

@emanuele_crupi @AndreaNecchi @IBCG_BladderCA

Access @EurUrolFocus article here:
https://t.co/XiVNwSkO9p
#bladdercancer #bladderpreservation